HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:HALO • US40637H1095

78.42 USD
+0.49 (+0.63%)
At close: Feb 5, 2026
78.14 USD
-0.28 (-0.36%)
After Hours: 2/5/2026, 8:00:02 PM
Fundamental Rating

7

Overall HALO gets a fundamental rating of 7 out of 10. We evaluated HALO against 524 industry peers in the Biotechnology industry. HALO has an excellent profitability rating, but there are some minor concerns on its financial health. HALO is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make HALO suitable for value and growth investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year HALO was profitable.
  • In the past year HALO had a positive cash flow from operations.
  • Each year in the past 5 years HALO has been profitable.
  • Each year in the past 5 years HALO had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • HALO has a Return On Assets of 26.81%. This is amongst the best in the industry. HALO outperforms 97.71% of its industry peers.
  • The Return On Equity of HALO (118.17%) is better than 99.62% of its industry peers.
  • HALO's Return On Invested Capital of 42.77% is amongst the best of the industry. HALO outperforms 99.24% of its industry peers.
  • HALO had an Average Return On Invested Capital over the past 3 years of 17.81%. This is in line with the industry average of 18.09%.
  • The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 26.81%
ROE 118.17%
ROIC 42.77%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • HALO has a Profit Margin of 47.91%. This is amongst the best in the industry. HALO outperforms 98.28% of its industry peers.
  • HALO's Profit Margin has declined in the last couple of years.
  • The Operating Margin of HALO (59.33%) is better than 100.00% of its industry peers.
  • HALO's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 84.55%, HALO belongs to the best of the industry, outperforming 87.21% of the companies in the same industry.
  • HALO's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 59.33%
PM (TTM) 47.91%
GM 84.55%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
  • HALO has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, HALO has less shares outstanding
  • Compared to 1 year ago, HALO has an improved debt to assets ratio.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 5.44 indicates that HALO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HALO (5.44) is better than 73.86% of its industry peers.
  • The Debt to FCF ratio of HALO is 2.51, which is a good value as it means it would take HALO, 2.51 years of fcf income to pay off all of its debts.
  • HALO has a better Debt to FCF ratio (2.51) than 93.13% of its industry peers.
  • A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
  • The Debt to Equity ratio of HALO (1.59) is worse than 76.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF 2.51
Altman-Z 5.44
ROIC/WACC5.28
WACC8.1%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 1.59 indicates that HALO should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.59, HALO is not doing good in the industry: 79.58% of the companies in the same industry are doing better.
  • HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
  • HALO has a worse Quick ratio (1.37) than 80.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.37
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 48.55% over the past year.
  • The Earnings Per Share has been growing by 30.12% on average over the past years. This is a very strong growth
  • The Revenue has grown by 31.19% in the past year. This is a very strong growth!
  • HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%

3.2 Future

  • HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.78% yearly.
  • Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 13.23% on average per year.
EPS Next Y50.81%
EPS Next 2Y40.55%
EPS Next 3Y32.4%
EPS Next 5Y17.78%
Revenue Next Year33.53%
Revenue Next 2Y29.85%
Revenue Next 3Y23.95%
Revenue Next 5Y13.23%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 13.93, HALO is valued correctly.
  • HALO's Price/Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 96.76% of the companies in the same industry.
  • HALO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.67.
  • The Price/Forward Earnings ratio is 9.39, which indicates a very decent valuation of HALO.
  • Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.47% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (27.20), we can say HALO is valued rather cheaply.
Industry RankSector Rank
PE 13.93
Fwd PE 9.39
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.56% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 96.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 15.31
EV/EBITDA 11.83
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HALO has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as HALO's earnings are expected to grow with 32.40% in the coming years.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y40.55%
EPS Next 3Y32.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HALO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/5/2026, 8:00:02 PM)

After market: 78.14 -0.28 (-0.36%)

78.42

+0.49 (+0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-24
Inst Owners105.85%
Inst Owner Change-2.25%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap9.22B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target78.67 (0.32%)
Short Float %11.69%
Short Ratio6.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)1.48%
PT rev (3m)1.93%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)1.13%
EPS NY rev (1m)-0.32%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)1.35%
Revenue NY rev (1m)-0.22%
Revenue NY rev (3m)1.56%
Valuation
Industry RankSector Rank
PE 13.93
Fwd PE 9.39
P/S 7.42
P/FCF 15.31
P/OCF 15.09
P/B 18.3
P/tB N/A
EV/EBITDA 11.83
EPS(TTM)5.63
EY7.18%
EPS(NY)8.36
Fwd EY10.66%
FCF(TTM)5.12
FCFY6.53%
OCF(TTM)5.2
OCFY6.63%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.27
PEG (5Y)N/A
Graham Number23.3
Profitability
Industry RankSector Rank
ROA 26.81%
ROE 118.17%
ROCE 53.28%
ROIC 42.77%
ROICexc 86.79%
ROICexgc N/A
OM 59.33%
PM (TTM) 47.91%
GM 84.55%
FCFM 48.47%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF 2.51
Debt/EBITDA 0.98
Cap/Depr 10.51%
Cap/Sales 0.69%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 101.16%
Current Ratio 1.59
Quick Ratio 1.37
Altman-Z 5.44
F-Score8
WACC8.1%
ROIC/WACC5.28
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y50.81%
EPS Next 2Y40.55%
EPS Next 3Y32.4%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year33.53%
Revenue Next 2Y29.85%
Revenue Next 3Y23.95%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A

HALOZYME THERAPEUTICS INC / HALO FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 7 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


Can you provide the profitability details for HALOZYME THERAPEUTICS INC?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.


What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?

The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.


Can you provide the expected EPS growth for HALO stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 50.81% in the next year.